Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy

• Status: Unknown status
• Trial end date: 2016-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the clinical safety and efficacy of QingReMoShen Granule to treat idiopathic membranous nephropathy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: wanglin
• Treatments: Losartan

Criteria

Inclusion Criteria:

• Women and men who had a clinic and biopsy-proven idiopathic membranous nephropathy;

• 6.0g≥24 hour urinary protein≥1.0g;

• serum albumin concentration≥26g/L;

• Chronic Kidney Disease (CKD)≤3 stage (eGFR>30ml/min/1.73m2 MDRD);

• Willing to participate in the trial and signed an informed consent.

Exclusion Criteria:

• Secondary membranous nephropathy;

• Patients with one of the following circumstances- malignant tumors or malignancy, HIV infection, a history of mental illness, any serious systemic infection, serious gastrointestinal diseases, circulating hepatitis B surface antigens positive or persistent abnormal serum transaminase, abnormal glucose metabolism or diabetes mellitus;

• Pregnant and lactating women;

• Undergoing other clinical trials.